Trulieve Cannabis price target raised to $16 from $12 at Seaport Research

Seaport Research raised the firm’s price target on Trulieve Cannabis to $16 from $12 and keeps a Buy rating on the shares. The company reported better than expected Q4 results with revenue and adjusted EBITDA handily beating consensus estimates, the analyst tells investors in a research note. The firm believes Trulieve’s “dominant” position in Florida, focus on automation and cost reduction, and strong balance sheet should create shareholder value “for years to come.”